Calcitonin Or Derivative Patents (Class 514/11.9)
  • Patent number: 10420721
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: September 24, 2019
    Assignee: Entera Bio Ltd.
    Inventors: Miriam Kidron, Ehud Arbit
  • Patent number: 9896481
    Abstract: Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: February 20, 2018
    Assignee: The Regents of the University of California
    Inventors: Tomas Ganz, Elizabeta Nemeth, Piotr Ruchala
  • Patent number: 9486947
    Abstract: The invention includes a tablet made from a coagulant that will improve the settling of suspended solids in an aqueous media such as wastewater, recycled water, potable water, storm water, swimming pool water, spa water, boiler water, cooling tower water and industrial process water. The agent is a tablet containing at least one salt from the aluminum sulfate family in a mixture of organic and inorganic binders. The mixed material is especially adapted to lend itself to high speed molding operations. Such agent, when in molded form, provides controlled dissolution in an aqueous media, exhibits strength and non-chipping characteristics which is a benefit in shipping and handling and is free from dusting, flaking or other deteriorative factors. In its tablet form, this agent can be used in combination with a holding apparatus having slotted opening zones.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: November 8, 2016
    Inventor: Gregory D. Graves
  • Patent number: 9133140
    Abstract: Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1): [wherein, Ar which is a partial structure in the general formula (1) represents a phenyl group or a naphthyl group; R1a and R1b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; R2a and R2b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; A represents a single bond, an oxygen atom, or the like; B represents a single bond, a C1-C4 alkanediyl group, or the like; Z represents a carboxyl group or a tetrazolyl group; and m represents an integer of 1 to 3] or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: September 15, 2015
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Shinji Marumoto, Toyoki Nishimata, Masayuki Ebisawa, Yusuke Asoh, Yasuo Fukushima, Mikio Kato
  • Publication number: 20150147282
    Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventors: Fredrik JOABSSON, Margareta LINDEN, Krister THURESSON, Fredrik TIBERG
  • Publication number: 20150148295
    Abstract: Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent.
    Type: Application
    Filed: February 9, 2015
    Publication date: May 28, 2015
    Inventors: Kevin Burton, Torsten Woehr, Thomas R. Tice, Mimoun Ayoub
  • Publication number: 20150125518
    Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 7, 2015
    Inventors: JOHN R. LAU, W. BLAIR GEHO
  • Publication number: 20150098909
    Abstract: A soluble fiber lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and one or more additives dispersed in the soluble-fiber matrix. In some cases, a soluble fiber lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in soluble fiber lozenge provided herein can include maltodextrin. The soluble fiber lozenge is adapted to release one or more additives from the body when the body is received within the oral cavity of a consumer and exposed to saliva. A method of making soluble fiber lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, one or more additives, and less than 15 weight percent water while maintaining a mixture temperature of less than 200° C. and portioning the molten mixture into a plurality of soluble fiber lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Feng Gao, Diane L. Gee, Shuzhong Zhuang, Phillip M. Hulan, William J. Burke, Gerd Kobal
  • Publication number: 20150093419
    Abstract: The invention provides a pharmaceutical composition comprising a mixture of (a) an active macromolecular principle, and (b) an aromatic alcohol absorption enhancer chosen from butylated hydroxy toluene, butylated hydroxy anisole and analogues and derivatives thereof, wherein the aromatic alcohol absorption enhancer is present in an amount by weight greater than or equal to that of the active macromolecular principle, and further comprises a pharmaceutical composition comprising a mixture of (a) an active macromolecular principle, (b) an aromatic alcohol absorption enhancer chosen from propyl gallate, butylated hydroxy toluene, butylated hydroxy anisole and analogues and derivatives thereof, wherein the aromatic alcohol absorption enhancer is present in an amount by weight greater than or equal to that of the active macromolecular principle, and (c) a solubilisation aid capable of increasing the solubility of the aromatic alcohol absorption enhancer in aqueous media.
    Type: Application
    Filed: December 4, 2014
    Publication date: April 2, 2015
    Inventor: ROGER R.C. NEW
  • Publication number: 20150064118
    Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
    Type: Application
    Filed: September 15, 2014
    Publication date: March 5, 2015
    Inventors: Krister THURESSON, Fredrik TIBERG, Markus JOHANSSON, Ian HARWIGSSON, Fredrik JOABSSON, Markus JOHNSSON
  • Patent number: 8968716
    Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: March 3, 2015
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
  • Publication number: 20150025006
    Abstract: One aspect of the present invention is a pharmaceutical combination comprising (a) an anti-inflammatory agent/anti-oxidant agent conjugate; and (b) an insulin secretogogue, an insulin sensitizer, an alpha-glucosidase inhibitor, a peptide analog, or a combination thereof. Another aspect of the invention relates to methods of treating metabolic disorders with such conjugates.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 22, 2015
    Applicant: Genmedica Therapeutics SL
    Inventors: Julio Cesar Castro Palomino Laria, Luc Marti Clauzel, Antonio Zorzano Olarte, Silvia Garcia Vicente, Alec Mian
  • Publication number: 20150004196
    Abstract: The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.
    Type: Application
    Filed: June 5, 2014
    Publication date: January 1, 2015
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Publication number: 20140369993
    Abstract: The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.
    Type: Application
    Filed: January 22, 2013
    Publication date: December 18, 2014
    Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer, Clive Wilson, Anthony Pettigrew, Annette Hüttig
  • Publication number: 20140356344
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
    Type: Application
    Filed: August 20, 2014
    Publication date: December 4, 2014
    Applicant: BioAtla LLC
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20140335169
    Abstract: Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.
    Type: Application
    Filed: January 17, 2014
    Publication date: November 13, 2014
    Applicant: Enteris BioPharma, Inc.
    Inventors: William Stern, Angelo P. Consalvo
  • Publication number: 20140329752
    Abstract: The embodiments provide a modified calcitonin gene-related peptide antagonist including an N-terminal fragment of modified calcitonin gene-related peptide or related protein family member where at least two residues of the N-terminal fragment are cysteine (Cys) and at least one amino acid comprises a non-threonine substitution of a threonine (Thr) residue; a central core where the central core comprises an oc-helix; and a C-terminal fragment of modified calcitonin gene-related peptide or related protein family member comprising a C-terminal amide and where at least one amino acid of the C-terminal fragment is phenylalanine (Phe), proline (Pro), tyrosine (Tyr) or hydroxyproline (Hyp) or pharmaceutically acceptable salt thereof, as well as compositions, including pharmaceutical compositions, comprising a subject peptide.
    Type: Application
    Filed: January 25, 2013
    Publication date: November 6, 2014
    Inventor: Christopher J. Soares
  • Patent number: 8877196
    Abstract: The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: November 4, 2014
    Assignee: OssiFi Inc.
    Inventor: Debra L. Ellies
  • Publication number: 20140322336
    Abstract: Provided, among other things, are compositions and methods for making sustained-release microspheres, as well as a microsphere delivery system for the sustained release of an active agent. The microsphere delivery system comprises a homogenous mixture of biodegradable polymer, active agent, and a so-called release-modifying agent (including a pH-stabilizing agent), and provides protected and sustained release of active agents from the microsphere delivery system. According to the invention, the microspheres preferably are produced by an oil-in-water emulsion method that involves the production of a homogeneous oil phase prepared by mixing active agent and a release-modifying agent, such as arginine, with biodegradable polymer, each dissolved in organic solvent.
    Type: Application
    Filed: July 11, 2014
    Publication date: October 30, 2014
    Inventors: Byung Ho WOO, Sumeet H. DAGAR, Kang Yong YANG
  • Publication number: 20140314853
    Abstract: A new microsphere formulation (composition) for controlled- or sustained-release delivery of therapeutic ingredient(s), mainly peptides and proteins not over 10K in molecular weight, comprises at least a therapeutic ingredient, a helping agent (such as PH sensitive agent whose solubility is a function of pH) and a biodegradable polymer. The therapeutic ingredient(s) and the helping agent are in the form of fine particles, less than 1O um in diameter, encapsulated in the polymer which forms the microsphere matrix. A method for preparing the composition comprises a step of in-situ precipitating the therapeutic ingredient(s) and the helping agent to the fine particles and successive steps for forming the microspheres. Such a microsphere formulation offers a well-controlled release profile for prolonged period and encapsulation efficiency over 95%.
    Type: Application
    Filed: December 5, 2012
    Publication date: October 23, 2014
    Inventors: Tuo Jin, Zhenhua Hu, Weien Yuan
  • Publication number: 20140271955
    Abstract: Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicants: The Scripps Research Institute, The California Institute for Biomedical Research
    Inventors: Peter G. SCHULTZ, Arnab K. CHATTERJEE, Shoutian ZHU, Joshua PAYETTE, Hongchul YOON, Baiyuan YANG
  • Publication number: 20140271735
    Abstract: The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.
    Type: Application
    Filed: June 2, 2014
    Publication date: September 18, 2014
    Applicant: Novartis AG
    Inventors: Moise Azria, Claus Christiansen, Simon David Bateman, Shoufeng Li
  • Publication number: 20140256623
    Abstract: Provided is a conjugate including a pharmacologically active substance covalently bound to chitosan or its derivative and a method for transmucosal delivery of a pharmacologically active substance using the same. Specifically a conjugate includes a pharmacologically active substance covalently bound via a linker to chitosan; and a pharmaceutical composition for transmucosal administration of a drug includes the aforementioned conjugate and a pharmaceutically acceptable carrier. Further provided is a method for in vivo delivery of a pharmacologically active substance via a transmucosal route, by covalent binding of the active substance with chitosan or its derivative via a linker.
    Type: Application
    Filed: May 23, 2014
    Publication date: September 11, 2014
    Applicant: ANYGEN CO., LTD.
    Inventors: Sangyong JON, EUNHYE LEE, JIN JU LEE, IN-HYUN LEE
  • Publication number: 20140249085
    Abstract: Calcitonin products and therapies for treating inflammatory or degenerative diseases are disclosed herein. The pharmaceutical compositions disclosed herein include a first therapeutic agent that is calcitonin, in free or salt form; a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid; and a pharmaceutically acceptable excipient, carrier or diluent.
    Type: Application
    Filed: October 4, 2013
    Publication date: September 4, 2014
    Applicant: UGP THERAPEUTICS, INC.
    Inventors: Nozer M. Mehta, James P. Gilligan
  • Publication number: 20140249076
    Abstract: Provided herein are amylin-calcitonin peptide conjugates having enhanced duration of biological activity, and methods of use thereof. The amylin-calcitonin peptide conjugates include duration enhancing moieties, such as water soluble polymers and long chain aliphatic groups, bound to the amylin-calcitonin peptide. Methods of use are provided for treatment of an eating disorder, insulin resistance, obesity, overweight, abnormal postprandial hyperglycemia, Type I diabetes, Type II diabetes, gestational diabetes, metabolic syndrome, dumping syndrome, hypertension, dyslipidemia, cardiovascular disease, hyperlipidemia, sleep apnea, cancer, pulmonary hypertension, cholescystitis or osteoarthritis.
    Type: Application
    Filed: October 17, 2012
    Publication date: September 4, 2014
    Inventors: Manoj P. Samant, Ved Srivastava, Odile Esther Levy, Christine M. Mack, William E. Rote
  • Publication number: 20140242153
    Abstract: Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.
    Type: Application
    Filed: January 30, 2014
    Publication date: August 28, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Raphael J. Mannino, Susan Gould-Fogerite, Sara L. Krause-Elsmore, David Delmarre, Ruying Lu
  • Publication number: 20140205648
    Abstract: The present invention relates to methods for in situ treatment of malignant cells from a cancer associated with bone. In one method, the treatment is for a primary cancer and entails positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a site containing the malignant cells. In another method, the treatment includes positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a surgical site from which malignant cells were previously removed/excised.
    Type: Application
    Filed: April 3, 2014
    Publication date: July 24, 2014
    Applicant: DePuy Synthes Products, LLC
    Inventor: Maria Maccecchini
  • Patent number: 8778403
    Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: July 15, 2014
    Assignee: Mannkind Corporation
    Inventors: Marshall L. Grant, Grayson W. Stowell, Paul Menkin
  • Publication number: 20140193360
    Abstract: The present invention relates to an adhesive hydrogel composition containing catechol group-coupled chitosan and Pluronic comprising a thiol group coupled to the end thereof, and more specifically, to an adhesive composition which is safe in vivo and in vitro, is temperature sensitive, and has an excellent hemostatic effect and thus can be used as a bioadhesive, and a medical adhesive, an adhesion barrier and a surface adsorption inhibitor comprising the same.
    Type: Application
    Filed: November 21, 2011
    Publication date: July 10, 2014
    Applicant: Innotherapy Inc.
    Inventors: Haeshin Lee, Moon Sue Lee, Ji Hyun Ryu
  • Publication number: 20140193347
    Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
    Type: Application
    Filed: September 4, 2013
    Publication date: July 10, 2014
    Applicant: CAMURUS AB
    Inventors: Krister THURESSON, Fredrik TIBERG, Markus JOHANSSON, Ian HARWIGSSON, Fredrik JOABSSON, Markus JOHNSSON
  • Patent number: 8772235
    Abstract: Described herein are compositions having a peptide sequence that includes at least one bone targeting moiety, wherein the bone targeting moiety is bonded to the peptide sequence by a linker, wherein the peptide sequence is calcitonin, and wherein the composition is neutral or a pharmaceutically acceptable salt or ester thereof. In one aspect, calcitonin inhibits or slows osteoclast mediated resorptive bone loss. The compounds described herein can be used in a number of therapeutic applications including treating or preventing conditions associated with bone loss, which include, but are not limited to, osteoporosis, Paget's disease, osteolytic tumors, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Osteoarthritis, osteopenia, and hypercalcemia. Also described herein are the methods of making these compositions that prevent or treat conditions associated with bone loss and methods of preventing bone fractures.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: July 8, 2014
    Assignee: The Governors of the University of Alberta
    Inventors: Michael R. Doschak, Krishna Hari Bhandari
  • Patent number: 8765675
    Abstract: The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: July 1, 2014
    Assignee: Novartis AG
    Inventors: Moise Azria, Claus Christiansen, Simon David Bateman, Shoufeng Li
  • Patent number: 8765676
    Abstract: Calcium-sensing receptor (CaSR) modulating substituted cyclopentylene compounds represented in formula I (wherein X is CH or N) and pharmaceutical compositions thereof are useful for treating diseases.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: July 1, 2014
    Assignee: Leo Pharma A/S
    Inventors: Bjarne Nørremark, Lars Kristian Albert Blæhr, Anne Eeg Knapp, Kristoffer Månsson
  • Patent number: 8748383
    Abstract: Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: June 10, 2014
    Assignees: Novartis AG, Emisphere Technologies, Inc.
    Inventors: Shoufeng Li, Anasuya Ashok Ghosh, Simon D. Bateman, Moise Azria, Alan E. Royce
  • Patent number: 8729019
    Abstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: May 20, 2014
    Assignee: Mannkind Corporation
    Inventors: Keith A. Oberg, Joseph Sulner
  • Publication number: 20140113012
    Abstract: The present invention provides compounds and compositions for the amelioration of arthritis and joint injuries by inducing mesenchymal stem cells into chondrocytes.
    Type: Application
    Filed: March 26, 2012
    Publication date: April 24, 2014
    Applicant: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Peter Schultz, Laure Bouchez
  • Publication number: 20140100163
    Abstract: This invention relates, e.g., to methods for inhibiting or stimulating an activity of an adrenomedullin (AM) or gastrin releasing peptide (GRP) peptide hormone, comprising contacting the peptide with a small molecule, non-peptide, modulatory agent of the invention. Complexes of these modulatory agents with other components, such as the peptides or blocking antibodies specific for the peptides, are also described, as are pharmaceutical compositions comprising the modulatory agents, and methods for using the modulatory agents to diagnose or treat patients.
    Type: Application
    Filed: December 11, 2013
    Publication date: April 10, 2014
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Frank Cuttitta, Alfredo Martinez
  • Publication number: 20140072531
    Abstract: A method for preparing polymer microparticles with a reduced initial burst, and the polymer microparticles prepared thereby, the method including: contacting polymer microparticles with an alcohol aqueous solution, the polymer microparticles prepared thereby, and use for drug delivery of the polymer microparticles.
    Type: Application
    Filed: November 20, 2013
    Publication date: March 13, 2014
    Applicant: SK CHEMICALS CO., LTD.
    Inventors: Hong Kee KIM, Kyu Ho Lee, Joon-Gyo OH, Bong-Yong Lee
  • Patent number: 8664178
    Abstract: Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: March 4, 2014
    Assignee: Enteris BioPharma, Inc.
    Inventors: William Stern, Angelo P. Consalvo
  • Publication number: 20140044790
    Abstract: Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing.
    Type: Application
    Filed: October 29, 2013
    Publication date: February 13, 2014
    Applicant: MannKind Corporation
    Inventors: Edwin Amoro, Karel Vanackere, Michael A. White
  • Publication number: 20140038894
    Abstract: In a first aspect, the invention provides a polymeric nanoparticle comprising at least one polycationic polymer; at least one polyanionic polymer; and a therapeutically effective amount of at least one therapeutic agent. In a second aspect, the invention provides a method for the preparation of a polymeric nanoparticle according to the first aspect; the method comprising the steps of: (i) admixing the at least one polyanionic polymer with the at least one therapeutic agent; and (ii) introducing to the mixture of (i), to the at least one polycationic polymer. In a third aspect, the invention provides a polymeric nanoparticle according to the first aspect of the present invention, or a polymeric nanoparticle prepared according to the second aspect of the present invention; for use in the treatment of an inflammatory and/or arthritic disorder caused by or associated with dysfunctional nuclear receptor signalling.
    Type: Application
    Filed: October 24, 2011
    Publication date: February 6, 2014
    Inventors: Owen Corrigan, Lidia Tajber, Sinead Ryan, David Brayden, Anita Umerska
  • Publication number: 20130330380
    Abstract: The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.
    Type: Application
    Filed: June 25, 2013
    Publication date: December 12, 2013
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Publication number: 20130331319
    Abstract: A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature.
    Type: Application
    Filed: July 22, 2013
    Publication date: December 12, 2013
    Inventors: Nicholas V. Perricone, Chim Potini
  • Patent number: 8598120
    Abstract: The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: December 3, 2013
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Christopher J. Soares, Michael R. Hanley, Diana Y. Lewis, David G. Parkes, Carolyn M. Jodka, Kathryn S. Prickett, Soumitra S. Ghosh, Christine M. Mack, Qing Lin
  • Patent number: 8592366
    Abstract: Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: November 26, 2013
    Assignee: Enteris Biopharma, Inc.
    Inventors: William Stern, Angelo P. Consalvo
  • Publication number: 20130303444
    Abstract: The present invention relates to crystalline polymorphic forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, pharmaceutical compositions containing the same, methods of preparing the same, and methods for facilitating the delivery of active agents with the same.
    Type: Application
    Filed: April 5, 2013
    Publication date: November 14, 2013
    Applicant: Emisphere Technologies, Inc.
    Inventors: Nikhil DHOOT, Steven DINH, Shingai MAJURU, William Elliott BAY, JoAnne P. CORVINO, Doris C. O'TOOLE
  • Patent number: 8580738
    Abstract: The present invention discloses methods to prevent and treat cardiovascular disorders, hi certain aspects the methods are drawn to releasing endogenous calcitonin-gene related peptide from intrinsic cardiac adrenergic cells within the heart. In further aspects, a combination of a ?2 adrenergic receptor agonist (?2-AR agonist) and a vasodilator can be used in treating reperfusion injury.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: November 12, 2013
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Ming-He Huang, Yochai Birnbaum, Barry F. Uretsky
  • Publication number: 20130295089
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Application
    Filed: July 11, 2013
    Publication date: November 7, 2013
    Inventors: John Knopf, Jasbir Seehra
  • Publication number: 20130287852
    Abstract: Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 31, 2013
    Inventors: Toshikazu OKI, Takashi HANAFUSA, Shunji HARUTA
  • Patent number: 8551528
    Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: October 8, 2013
    Assignee: Mannkind Corporation
    Inventors: Marshall L. Grant, Grayson W. Stowell, Paul Menkin